Tildrakizumab is an IL-23 inhibitor that has previously demonstrated efficacy combined with favourable safety data for 3 years in patients with moderate-to-severe plaque psoriasis in phase 3 trials [1,2]. In these randomised, controlled studies, adults were treated with tildrakizumab 100 mg or 200 mg or placebo at weeks 0 and 4, and subsequently every 12 weeks. The reSURFACE 2 (NCT01729754) trial also included an arm with the active comparator etanercept [2]. After the base studies, patients eligible to enter the extension part of the trials were continued on tildrakizumab according to their response or previous study arm within the base trial. Hence, the extension included 506 patients of reSURFACE 1 (NCT01722331) and 730 of reSURFACE 2 [3].
As long-term safety is of major interest in chronic inflammatory diseases such as psoriasis, the new post-hoc analysis of the pivotal large reSURFACE 1 and 2 trials assessed rates of serious and drug-related infections over 5 years of drug exposure. To evaluate safety, all patients who received ≥1 dose in the extension phase of the same medication as in the base study were investigated for infections categorised as serious adverse events (SAE), as well as all infections. The analysed exposure to tildrakizumab equalled over 2,800 patient-years (PY) of 100 mg and over 2,900 PY of 200 mg. Mean age of the participants ranged from 44.2 to 47.1 in the different study arms, mean baseline Psoriasis Area Severity Index (PASI) score varied between 19.3 and 21.3.
The exposure-adjusted incidence rate for SAE infections in reSURFACE on both dosages of tildrakizumab was ≤1/100 PY, whereas exposure-adjusted incidence rate for serious drug-related infections was ≤0.3/100 PY. Most reported serious infections were diverticulitis, appendicitis, and gastroenteritis. Most frequently drug-related infections were nasopharyngitis, upper respiratory tract infections, and bronchitis; in reSURFACE 2 also rhinitis. In conclusion, no indications of new safety issues emerged and the exposure-adjusted incidence rate for drug-related infections over 5 years can be considered overall low and comparable between the 100 mg and 200 mg doses.
- Reich, K, et al. Br J Dermatol. 2020;182(3):605–17.
- Reich K, et al. Lancet. 2017;390:276–88.
- Gebauer K, et al. Serious infections and infections related to study drug and leading to discontinuation through 5 years of tildrakizumab exposure in 2 phase 3 clinical trials. Poster 25363, AAD VMX 2021, 23-25 April.
Copyright ©2021 Medicom Medical Publishers
Posted on
Previous Article
« No increased risk of infection with long-term dupilumab for atopic dermatitis Next Article
Nicotinamide and probiotics can support acne therapy »
« No increased risk of infection with long-term dupilumab for atopic dermatitis Next Article
Nicotinamide and probiotics can support acne therapy »
Table of Contents: AAD 2021
Featured articles
Letter from the Editor
Late-Breaking Abstracts
Small molecule effective in moderate-to-severe psoriasis
Bruton’s tyrosine kinase inhibition promising for pemphigus vulgaris
Bimekizumab superior to secukinumab in psoriasis
Etrasimod – a new mode of action for treatment of atopic dermatitis
Women at higher risk for dermatologic side effects during immunotherapy
Novel easy-to-use foam formulation clears scalp psoriasis in one-third of patients
Anti-cholinergic gel demonstrates superior long-term tolerability and efficacy in axillary hyperhidrosis
Psoriasis – The Beat Goes On
Psoriasis: The treatment armamentarium continues to grow
Psoriasis management in times of COVID-19: the knowledge is growing steadily
Lower burden of high-risk atherosclerotic plaques in psoriasis patients treated with biologics
COVID-19: What Dermatologists Need to Know
Psoriasis and hidradenitis suppurativa during COVID-19: keep calm and carry on
COVID-19 in children – cutaneous involvement is common
Cutaneous reactions after COVID-19 vaccination: an update
Novel Developments in Sun Protection
Sunless tanning and other developments in sun protection
What Is Hot in Atopic Dermatitis
Comorbidity is common in adult and paediatric atopic dermatitis patients
Significant improvements in the system armamentarium for AD treatment
Topical pan-JAK inhibitor cream safe and efficacious in atopic dermatitis
Hairy Matters – What Is New in Alopecia
Allergies: an underrated factor in alopecia pathogenesis
Botulinum toxin A: a contradictory role in hair loss
Platelet-rich plasma in androgenetic alopecia – hype or hope?
Acne – New Developments
New therapeutic options add value to current acne treatment
Nicotinamide and probiotics can support acne therapy
Pearls of the Posters
Related Articles
July 31, 2023
Vascular inflammation may be characteristic of PsA
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com